重组白细胞介素2治疗恶性胸腔积液的前瞻性研究  

PROSPECTIVE STUDY ON THE TREATMENT OF MALIGNANT PLEURAL EFFUSIONS WITH rIL-2

作　　者：申良方[1] 涂青松[1] 杨振[1] 袁君[1] 洪继东[1] 王龙云[1] 李建璜[1] 雷鸣军[1] 

机构地区：[1]中南大学湘雅医院放疗科,长沙410008

出　　处：《中国现代医学杂志》2002年第11期57-58,61,共3页China Journal of Modern Medicine

摘　　要：目的 :探讨重组白细胞介素 2 (rIL - 2 )治疗恶性胸腔积液的临床应用价值。方法 :1998年 3月～ 2 0 0 1年8月收治的 79例癌性胸腔积液患者随机分为rIL - 2治疗组和顺铂 (DDP)对照组 ,rIL - 2治疗组 4 0例采用rIL - 2胸腔内给药 ,每次 10 0～ 16 0万u ,每周 2次 ,2～ 4周为一疗程。DDP对照组采用DDP胸腔内给药 ,每次 80～ 10 0mg ,每周 1次 ,2～ 4周为一疗程。结果 :rIL - 2治疗组总有效率 85 % ,与DDP对照组 84 .6 %比较无显著差异 (P >0 .0 5 )。胸痛、骨髓抑制、消化道反应的发生率rIL - 2组显著低于DDP组 (P <0 .0 5 )。生活质量改善rIL - 2组显著高于DDP组 (P <0 .0 5 )。结论 :rIL - 2对癌性胸水有显著的疗效 ,与化疗药物有相等的控制胸水的作用 ,能显著提高患者生活质量 ,且毒副作用小 ,患者易于接受。Objective:To evaluate the clinical value of the treatment of malignant pleural effusions with rIL-2.Methods:Seventy-nine patients treated in our hospital from March,1998 to August ,2001 were randomly divided into the rIL-2 group(40 patients) and DDP group (39 patients).The patients in rIL-2 group received rIL-2 100-160 unit per time ,twice a week,2～4 weeks one period of the treatment in thorax. The patients in DDP groups received DDP 80～100mg per time ,once a week,2～4 weeks one period of the treatment in thorax. Results:The curative rate in rIL-2 group (85%) was not significantly different form that in the DDP group (84.6%)( P >0.05).The rate of the chest ache and the marrow restraint and the enteron reaction in rIL-2 group was remarkablely lower than that in DDP group( P <0.05).The improvement extent of the living quality in rIL-2 group was significantly higher than that in DDP group( P <0.05).Conclusion:The therapeutic effect on malignant pleural effusions with rIL-2 is notable ,which has equivalent effects on the control of the malignant pleural effusions with chemotherapy.RIL-2 can improve the living quality of the patient markedly with little side-effect ,and is easily acceptable to patients.

关 键 词：RIL-2 顺铂 恶性胸腔积液 重组白细胞介素2 治疗 

分 类 号：R561.3[医药卫生—呼吸系统] R730.5[医药卫生—内科学]